Xylem (NYSE: XYL) EVP & Chief Legal Officer receives option and stock grants

Rhea-AI Filing Summary

Xylem Inc. executive Stacy Cozad, EVP & Chief Legal Officer, reported equity awards under the company’s incentive plan. She received 5,570 non-qualified stock options at an exercise price of $128.98 per share and 1,563 shares of common stock as a grant.

Both the options and the restricted stock units are scheduled to vest in one-third increments on March 1, 2027, March 1, 2028, and March 1, 2029. Following these transactions, she directly holds 5,570 options and 2,303 shares of common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Cozad Stacy

Role EVP & Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Options (Right to Buy)	5,570	$128.98	$718K
Grant/Award	Common Stock	1,563	$0.00	--

Holdings After Transaction: Non-Qualified Stock Options (Right to Buy) — 5,570 shares (Direct); Common Stock — 2,303 shares (Direct)

Footnotes (1)

1. Reflects an award of restricted stock units pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in one third increments on March 1, 2027, March 1, 2028 and March 1, 2029. Reflects an award of non-qualified stock options pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in one-third increments on March 1, 2027, March 1, 2028 and March 1, 2029.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cozad Stacy

(Last) (First) (Middle)

C/O XYLEM INC.

301 WATER STREET SE

(Street)

WASHINGTON DC 20003

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Xylem Inc. [ XYL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		A		1,563(1)	A	$0	2,303	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Options (Right to Buy)	$128.98	03/02/2026		A		5,570		(2)	03/02/2036	Common Stock	5,570	$128.98	5,570	D

Explanation of Responses:

1. Reflects an award of restricted stock units pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in one third increments on March 1, 2027, March 1, 2028 and March 1, 2029.

2. Reflects an award of non-qualified stock options pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in one-third increments on March 1, 2027, March 1, 2028 and March 1, 2029.

	/s/ Mike Nazario, by power of attorney for Stacy Cozad	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Xylem (XYL) report for Stacy Cozad?

Xylem reported that EVP & Chief Legal Officer Stacy Cozad received equity awards, including stock options and restricted stock units. These awards are part of the company’s long-term incentive compensation and follow a multi-year vesting schedule tied to specific future dates.

How many stock options were granted to Xylem (XYL) executive Stacy Cozad?

Stacy Cozad was granted 5,570 non-qualified stock options with an exercise price of $128.98 per share. These options were awarded under Xylem’s 2011 Omnibus Incentive Plan and will vest in three equal installments over the next several years.

What stock grants did Stacy Cozad receive in Xylem (XYL) common shares?

She received a grant of 1,563 shares of common stock, reported as restricted stock units with a grant price of $0.00. These units are scheduled to vest in three one-third increments on future March 1 dates, aligning with the company’s incentive plan.

What is the vesting schedule for Stacy Cozad’s Xylem (XYL) equity awards?

Both the restricted stock units and the non-qualified stock options vest in one-third increments on March 1, 2027, March 1, 2028, and March 1, 2029. This staggered schedule is designed to promote long-term alignment with shareholder interests.

How many Xylem (XYL) shares does Stacy Cozad own after these transactions?

After the reported grants, Stacy Cozad directly holds 2,303 shares of Xylem common stock and 5,570 non-qualified stock options. These holdings reflect equity-based compensation rather than open-market share purchases or sales by the executive.

Under which plan were Stacy Cozad’s Xylem (XYL) awards granted?

The equity awards were granted under the Xylem 2011 Omnibus Incentive Plan, as amended and restated on February 24, 2016. This plan governs grants of restricted stock units and stock options to eligible employees, including senior executives like Stacy Cozad.